Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and Chugai Pharma France, have joined hands to develop a smart textile that will assess and monitor the long-term joint health of patients. The smart textile will help in “real-life” monitoring of the impact of chronic pathologies on patients' articular health.
Initiated as part of the second season of the Digital Pharma Lab programme, the partnership between Chronolife and the Chugai Pharma France laboratory aims to develop a smart textile for “real-life” monitoring of the impact of chronic pathologies on patients' articular health.Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and Chugai Pharma France, have joined hands to develop a smart textile that will assess and monitor the long-term joint health of patients. The smart textile will help in “real-life” monitoring of the impact of chronic pathologies on patients' articular health.#
The purpose of this device is to enable remote assistance and diagnosis in order to promote the "continuum of care" between the hospital, the ambulatory and a patient's home. If successful, real-time processing of qualified alerts will enable rapid and appropriate therapeutic decisions to be made in the event of significant variations in the state of patients' joint health, with the aim to significantly improve their quality of life.
"We are very proud to support Chugai Pharma France in this ambitious project. It is a recognition of Chronolife's expertise in the design and development of innovative connected medical devices, applicable to specific use cases. This project is a continuation of our Keesense solution, a multiparametric connected t-shirt, certified CE Class Ila, that provides remote monitoring for patients with chronic cardiac, respiratory pathologies or Covid patients," says Laurent Vandebrouck, CEO of Chronolife.
"It is with great enthusiasm and humility that we start this innovative project with Chronolife. With enthusiasm as we hope to be able to provide an innovative and concrete solution aiming at improving the follow-up and joint health of patients. With humility because this is an exploratory and experimental initiative and we cannot at this stage predict the results. Transforming an innovative idea into a concrete solution will be an exciting journey and perfectly reflects the pioneering spirit that drives us at Chugai Pharma France," says Nicolas Henriot, president of Chugai Pharma France.
Fibre2Fashion News Desk (SV)
News
Articles
Interviews
Webinars
Events
Advertise with us
About Us
Contact Us
Privacy Policy
Terms & Conditions
Cookie Policy
